The applicability of liver transplantation for ALD remains limited because of ethical arguments and also because of the perception of poor outcome after transplantation. Patients with alcoholic cirrhosis are known to do as well as patients with nonalcoholic liver disease after receiving liver allogr
Quality of life after liver transplantation for hepatitis C infection
β Scribed by Tracey Dudley; Dawn Chaplin; Collette Clifford; David John Mutimer
- Publisher
- Springer Netherlands
- Year
- 2007
- Tongue
- English
- Weight
- 179 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0962-9343
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The aims of this pilot study were to evaluate the safety and efficacy of interferon-alpha 2b for treatment of hepatitis C virus infection in liver transplant recipients, to monitor changes in hepatitis C virus RNA levels with treatment and to determine pretreatment parameters predictive of a complet
## Identification of the hepatitis C virus-the main cause of posttransfusion and sporadic non -A, non-B hepatitisand the development of a diagnostic serological test have allowed us to study possible recurrence of this type of hepatitis after liver transplantation. Six of 34 consecutive transplant
1. Early recurrence of hepatitis C is universal. 2. Typical histopathologic features of hepatitis C virus (HCV) and acute allograft rejection (AAR) exist. 3. Early recurrent HCV may be differentiated from AAR. 4. Liver biopsy plays a role in diagnosing HCV and AAR. 5. Risk factors for recurrent HCV
Hepatitis C virus-induced liver disease is becoming a main indication for liver transplantation. Recurrence of hepatitis after transplantation has been reported, but its long-term consequences are unknown. Seventynine patients positive for hepatitis C virus (group 1) and 106 subjects negative for he
with treatment failures moving on to combination therapy (IFN/CMB). The primary difference between the two best strategies (IFN/CBM vs. CMB-G) was that the CMB-G strategy was more successful with those with genotype 1. Thus, the genotyping strategy reached more people with less responsive disease th